Antidiabetic activity of Embelia ribes , embelin and its derivatives: A systematic review and meta-analysis

• Published in: Biomedicine & pharmacotherapy Vol. 86; pp. 195 - 204
• Main Authors: Durg, Sharanbasappa, Veerapur, Veeresh P, Neelima, Satrasala, Dhadde, Shivsharan B
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.02.2017
• Subjects: Alloxan monohydrate; Animals; Blood glucose; Diabetes Mellitus - drug therapy; Diabetes Mellitus - metabolism; Embelia; Embelia ribes; Humans; Hypoglycemic Agents - isolation & purification; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Insulin; Internal Medicine; Medical Education; Meta-analysis; Oxidative Stress - drug effects; Oxidative Stress - physiology; Plant Extracts - isolation & purification; Plant Extracts - pharmacology; Plant Extracts - therapeutic use; Streptozotocin; Blood glucose; Embelia ribes; Alloxan monohydrate; Insulin; Streptozotocin; Meta-analysis
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2016.12.001

Abstract Embelia ribes ( ER ) has been documented in Ayurveda for treating various diseases, including diabetes mellitus (DM). The present systematic review and meta-analysis evaluated the efficacy and safety of ER and its active bio-marker, embelin and its derivatives in the treatment of DM. Literature search was performed in PubMed/MEDLINE, EMBASE, Scopus, ScienceDirect, Scifinder, and Google Scholar. Using Review Manager, meta-analysis of ER /embelin/derivatives of embelin versus diabetic control was performed with inverse-variance model, providing mean differences (MDs) and 95% confidence intervals (CIs). Heterogeneity was determined by I2 statistic. A total of 13 studies were included in the systematic review and meta-analysis, and were conducted in experimental rats. ER and embelin significantly ( P ≤ 0.01) resorted blood glucose (MD, −231.30; CI, −256.79, −205.82; and MD, −154.70; CI, −168.65, −140.74) and glycosylated haemoglobin (MD, −6.36; CI, −8.33, −4.39; and MD,−4.68; CI, −7.76, −1.60), respectively. Meta-analysis findings also reported considerable restoration of insulin, lipid profile, haemodynamic parameters, serum and oxidative stress markers. The derivatives of embelin, 6-bromoembelin and vilangin, also improved diabetic condition. In addition, treatments also ameliorated body weight changes due to diabetes. The present systematic review and meta-analysis supports scientific evidence for the antidiabetic activity of ER /embelin/derivatives of embelin. However, further research is warranted in clinical trials to validate the present findings.